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Insulin production by the pancreatic b-cell is required
for normal glucose homeostasis. While key transcription
factors that bind to the insulin promoter are known, rel-
atively little is known about the upstream regulators of
insulin transcription. Using a whole-genome RNA inter-
ference screen, we uncovered 26 novel regulators of
insulin transcription that regulate diverse processes in-
cluding oxidative phosphorylation, vesicle traffic, and
the unfolded protein response (UPR). We focused on
Spry2—a gene implicated in human type 2 diabetes by
genome-wide association studies but without a clear
connection to glucose homeostasis. We showed that
Spry2 is a novel UPR target and its upregulation is
dependent on PERK. Knockdown of Spry2 resulted
in reduced expression of Serca2, reduced endoplasmic
reticulum calcium levels, and induction of the UPR. Spry2
deletion in the adult mouse b-cell caused hyperglycemia
and hypoinsulinemia. Our study greatly expands the com-
pendium of insulin promoter regulators and demonstrates
a novel b-cell link between Spry2 and human diabetes.
Worldwide, 354 million people have diabetes, and this is
projected to increase to 592 million by the year 2035 (1).
The majority of this rise will be in type 2 diabetes, although
the incidence of type 1 diabetes also continues to rise
(2,3). The pathophysiological common ground of diabetes
is b-cell dysfunction and loss. Genome-wide association
studies of patients with type 2 diabetes have identified
approximately eighty risk loci, many of which are located
near genes that would be predicted to affect b-cell function
(reviewed by Morris [4]). However, only a few of the iden-
tified single nucleotide polymorphisms (SNPs) have been
experimentally verified to work through the genes to which
they have been assigned. We hypothesized that augment-
ing current genome-wide association studies results with
unbiased screens for the genes that control normal b-cell
function would reveal novel targets for future diabetes
therapeutics and generate a more complete picture of the
genes involved in the pathogenesis of human diabetes.
We performed a whole-genome RNA interference (RNAi)
screen for regulators of the human insulin promoter. We
identified novel regulators of insulin production including a
type 2 diabetes locus, Spry2 (5–7). Spry2 is known to nega-
tively regulate growth factor signaling, but its link to diabe-
tes is not clear. We discovered a novel role for Spry2 in the
unfolded protein response (UPR) and established it as a UPR
target. Our study provides a blueprint for functionally an-
notating the b-cell insulin production pathway and reveals a
novel mechanism linking Spry2 to human diabetes.
RESEARCH DESIGN AND METHODS
Cells and RNAi Screen
MIN6 cells were a gift from Dr. J. Miyazaki (Osaka Univer-
sity). The screening MIN6 cell line, containing a lentivirally
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delivered copy of the human insulin promoter driving
EGFP and a distinct integrated copy of the rous sarcoma
virus (RSV) promoter driving mCherry, was previously
described (8). A total of 1.25 pmol of each small inter-
fering RNA (siRNA) from the Qiagen Whole Genome
Mouse siRNA library version 1.0 was placed individu-
ally into wells of 384-well plates. Totals of 0.05 mL of
RNAiMax (Life Technologies) and 9.95 mL of Opti-MEM
(Life Technologies) followed by 10,000 reporter MIN6
cells in 40 mL of growth media (DMEM high glucose,
10% FBS, penicillin, streptomycin) were added to each
well. Five days after transfection, fluorescence was read
using an Analyst HT (Molecular Devices). GFP fluores-
cence was divided by mCherry fluorescence. Wells with
mCherry fluorescence 1.5 SD below the mean of that
plate were removed because of presumed cellular toxic-
ity. Scores were median two-way polished to remove
edge effects. A subset of the whole-genome library was
repeated using 0.5 mL of HiPerFect (Qiagen) and 9.5 mL
of Opti-MEM (Life Technologies) per well instead of
RNAiMax. Transfection efficiency for both reagents
was typically .90%.
Quantitative RT-PCR
Total RNA was prepared with TRIzol Reagent (Life
Technologies) followed by DNA digestion with TURBO
DNase (Ambion). Oligo-dT– and random hexamer–primed
cDNA was synthesized with SuperScript III (Life Technol-
ogies). For TaqMan primers, the delta-delta CT method was
used using the average CT of b-actin, b-glucuronidase,
cyclophilin, and TBP as reference genes. For SYBR Green
primers, data were normalized to b-actin. Primer se-
quences are listed in Supplementary Table 4.
mRNA-Seq
A single RNA isolation from the screening cell line was
used to generate a polyA-primed mRNA-Seq library as pre-
viously described, except Cufflinks 2.0.2 was used for the
fragments per kilobase of transcript per million mapped
reads (FPKM) determination (9,10). Reads have been de-
posited in the National Center for Biotechnology Infor-
mation Sequence Read Archive (SAMN06250888).
Gene Ontology Term Enrichment
Database for Annotation, Visualization and Integrated
Discovery v6.7 was used to find enriched gene ontology
(GO) terms (11).
Mice
Spry2 floxed mice were a gift from Dr. O. Klein (University
of California, San Francisco). Mouse insulin promoter–
CreERT (MIP1-CreERT) mice were a gift from Dr. N.
Tamarina (University of Chicago). Mice received three
subcutaneous 2-mg tamoxifen injections (Sigma-Aldrich)
at 6 weeks of age; each injection was separated by a day.
Intraperitoneal glucose tolerance testing was performed
at 12 weeks: 2 g/kg glucose was injected into the perito-
neal space after a 6-h fast, and blood glucose was moni-
tored with a FreeStyle Lite Glucometer (Abbott). Glucose
tolerance P values between the three genotypes were cal-
culated using a one-way ANOVA with repeated mea-
sures followed by pairwise comparisons corrected with
the Benjamini-Hochberg method for multiple testing. The
glucose area under the curve above fasting was measured
using the trapezoidal method. Insulin tolerance tests were
performed at 14 weeks: after a 6-h fast, 0.1 mU/gram body
weight of regular insulin was injected into the peritoneal
space. Plasma insulin levels were measured at 15 weeks:
after a 16-h fast and after a 2 g/kg intraperitoneal glucose
injection. Islets were isolated as previously described (12).
RNA was harvested with TRIzol 1 day after isolation.
Western Blots
Cells were lysed in buffer containing the following:
50 mmol/L TrisHCl pH 6.7, 150 mmol/L NaCl, 1% Triton
X-100, cOmplete Protease Inhibitor Cocktail (Roche), Phos-
phatase Inhibitor Cocktail 2 (Sigma-Aldrich), and Phospha-
tase Inhibitor Cocktail 3 (Sigma-Aldrich). The following
antibodies were used: anti-Wfs1 (11558–1-AP; Proteintech),
phospho-PERK (3179; Cell Signaling), phospho-Eif2a (3398;
Cell Signaling), total Eif2a (9722S; Cell Signaling), total
PERK (3192S; Cell Signaling), GAPDH (G8795; Sigma-
Aldrich), Spry2 (ab50317; Abcam), and Serca2 (sc-8095;
Santa Cruz Biotechnology). Islet protein samples were iso-
lated from the TRIzol Reagent organic phase after RNA iso-
lation as described in the protocol, except the pellet was
resuspended in 5 mol/L urea in 0.5% SDS.
D1ER Calcium Measurements
Unmodified MIN6 cells were infected with a lentivirus
expressing endoplasmic reticulum (ER)-targeted fluorescent
cameleon D1ER. If indicated, the cells were transfected with
the indicated siRNAs and rested for 5 days prior to analysis.
For measurement of ER cells low in calcium, the cells were
trypsinized and resuspended in complete media. Flow cyto-
metry was performed using an Attune Cytometer (Life
Technologies) using VL2 and VL1 as the fluorescence
resonance energy transfer (FRET) emission channel and
the CFP (donor) channel, respectively. VL2 was divided by
VL1 to calculate the FRET signal. The FRET low population
was defined as those having .33% reduction in the FRET
signal compared with the geometric mean of the popula-
tion. FRET low was typically 5–8% of the cell population for
the control siRNA transfection.
siRNAs
Anti-luciferase siRNA, AllStars Negative Control siRNA,
and Negative Control siRNA were obtained from Qiagen.
Annexin V Staining
Parental MIN6 cells were stained with Annexin V Alexa
Fluor 488 & Propidium Iodide (Life Technologies) and
analyzed by flow cytometry (Attune; Life Technologies).
The percentage of total events that were annexin V pos-
itive and propidium iodide negative is shown. For percent
cell death, MIN6 cells were trypsinzed and the percentage
of events in the live gate determined by forward and side
scatter was subtracted from 100%.
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Statistics
Unless otherwise specified, P values were calculated by two-
tailed Student t test and corrected for false discovery using
the Benjamini-Hochberg method. For quantitation of West-
ern blot bands (phospho-PERK, phospho-Eif2a, Spry2 in-
duction by UPR inducers, Spry2 or Wfs1 knockdown), the
log-transformed ratio of the experimental condition to the
control condition was used for a one-sample Student t test.
RESULTS
Whole-Genome RNAi Screen for Regulators of the
Insulin Promoter
To elucidate genes that alter insulin transcription, we
previously generated a MIN6 mouse insulinoma clonal
cell line that harbors an EGFP reporter driven by the
proximal 362 bases of the human insulin promoter. To
avoid selecting hits that affect general transcription, this
line was engineered to constitutively express a control
mCherry reporter driven by the RSV promoter (8). This
reporter cell line was used in a high-throughput RNAi
screen using a commercial library containing 75,366
unique siRNAs targeting ;22,000 mouse genes with 3–
4 unique siRNAs per gene. Each siRNA was individually
reverse transfected into the reporter cell line in 384-well
plates. Five days after transfection, the ratio of GFP to
mCherry fluorescence was measured (Fig. 1A). The plate-
based assay performance metric Z9 typically ranged from
0.6–0.8 (0.5 is considered acceptable; Supplementary
Fig. 1A) (13). Gene-level P values for positive regula-
tors of insulin expression (reduced GFP/mCherry) were
Figure 1—Whole-genome RNAi screen reveals novel regulators of the insulin promoter. A: Screen schematic: MIN6 cells expressing EGFP
under control of the insulin promoter and mCherry (mCh) under control of the RSV promoter are transfected with siRNAs in 384-well plates,
and GFP and mCherry are read out by a plate reader. B: 2log(p) value for positive regulator genes screened as determined by RSA. C:
Enriched GO term categories with enrichment scores [2log(p)]. D: GFP/mCherry fluorescence for siRNAs during secondary screening
normalized (norm) to control anti-luciferase siRNA. Each point represents the GFP/mCherry fluorescence compared with control with SEM.
siRNAs are ordered by RSA rank for positive regulators (right cluster), randomly selected from all siRNAs (center cluster), or ordered by RSA
rank for negative regulators (left cluster). n $3. For FDR-corrected P values, see Supplementary Table 2. E: Criteria used for selection of
siRNAs for secondary screening and overall confirmation rates. IPA, Ingenuity Pathway Analysis.
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determined using the redundant siRNA analysis (RSA),
where P values are assigned based on the number and
strength of siRNAs to that gene (14).
A portion of the screen was repeated with an alternative
lipid transfection reagent to ensure results were not
specific to the transfection reagent used. Normalized scores
for each siRNA were well correlated (Supplementary Fig.
1B), and gene-level P values for positive regulators of in-
sulin transcription were also well correlated (Supplemen-
tary Fig. 1C). To reduce off-target effects, we did not
further consider siRNAs targeting genes that were not
expressed using mRNA-Seq of the screening cell line (Sup-
plementary Table 1). As would be expected, the fraction of
hits that were not expressed in the screening cell line in-
creased as more inferior hits were considered (Supplemen-
tary Fig. 1D).
When ranked based on low GFP/mCherry (i.e., specific
suppression of insulin expression), the key b-cell tran-
scription factors, Glis3, Pdx1, and Neurod1, were ranked
3rd, 17th, and 29th, respectively (Fig. 1B), providing
strong validation for the screen. Wfs1, a known regulator
of both insulin production and insulin secretion, was also
identified. GO terms involving mitochondria, DNA tran-
scription, vesicular transport, and cytoskeleton were sig-
nificantly enriched among the top 300 genes that, when
knocked down, reduced GFP/mCherry (Fig. 1C).
To validate the primary screen, we retested the top
40 siRNAs targeting putative positive regulators, selecting
the top 2–3 performing siRNAs for each gene by GFP/
mCherrry reduction. These siRNAs were transfected into
the screening cell line in biological triplicate, and GFP and
mCherry were measured. Of the top 40 siRNAs targeting
putative positive regulators, 36 (90%) reduced GFP/mCherry
compared with a control siRNA during retesting. Of 50 ran-
dom siRNAs selected from the library, only one showed a
statistically significant reduction in GFP/mCherry (Fig. 1D).
We then selected additional siRNAs for retesting based on
b-cell expression, interconnectivity (based on GO term en-
richment), and published data for a specific role in b-cell
function (Fig. 1E). In total, 141 siRNAs targeting positive
regulators were tested in the screening assay with RSA ranks
up to 6,313. A total of 112/141 (79%) showed a statistically
significant reduction in GFP/mCherry compared with a con-
trol siRNA (Fig. 1E and Supplementary Table 2).
As GFP/mCherry fluorescence is a surrogate for insulin
promoter activity, siRNAs were tested for their ability to
reduce endogenous, unspliced insulin mRNA, as this has a
shorter half-life than mature insulin message (15,16). We
used a quantitative RT-PCR (qRT-PCR) assay for preIns1
mRNA, as we found that this was more sensitive to Pdx1,
Glis3, and NeuroD1 knockdown than preIns2 mRNA (data
not shown). A total of 78/108 (72%) siRNAs reduced pre-
Ins1mRNA. We considered genes with two siRNAs showing
reduced preIns1 mRNA as high-confidence hits. We found
29 such genes, 26 of which did not have a known role in
insulin promoter activity. An additional 15 genes had one of
two siRNAs reduce insulin mRNA levels (Fig. 2A). With the
exception of three genes without a known human ortholog,
all of our validated hits are expressed in human islets at
reads per kilobase of transcript per million mapped reads
(RPKM).0.1, suggesting that they could play a similar role
in insulin production in human b-cells (Supplementary Ta-
ble 3) (17). Although the screen was not optimized to detect
increases in GFP/mCherry, when the siRNAs were ranked
according to increased GFP/mCherry (targeting putative
negative regulators), the top 40 siRNAs did tend to subtly
increase GFP/mCherry during retesting (Fig. 1D). However,
a low rate of these siRNAs increased preIns1 mRNA (data
not shown), so we focused on the positive regulators.
To begin to validate our screen in vivo, we examined global
knockout (ko) mice of Gpr75, one of the G-protein–coupled
receptor hits in the screen. We found that Gpr75 ko mice
were modestly hyperglycemic compared with their wild-type
(wt) or heterozygous littermates (Supplementary Fig. 2A and
B), despite being more insulin sensitive and having lower
body weight (Supplementary Fig. 2C and D). Plasma insulin
levels were lower before and after a glucose challenge in
Gpr75 ko mice as compared with their wt littermates (Sup-
plementary Fig. 2E). Finally, insulin secretion in vitro was also
blunted in islets from Gpr75 ko mice (Supplementary Fig. 2F).
These data show that our in vitro whole-genome RNAi screen
was capable of detecting in vivo regulators of b-cell function.
Spry2 Is a Novel Regulator of b-Cell Insulin
Transcription
Among the other novel hits, we were particularly in-
terested in Spry2 because it has been identified in multiple
studies as a type 2 diabetes risk locus (5,7). We first
returned to the original confirmation qRT-PCR for preIns1.
Of the two Spry2 siRNAs initially retested, only Spry2_4 sta-
tistically significantly reduced preIns1 mRNA; Spry2_6
had a weaker effect and a false discovery rate (FDR)-
adjusted P value of 0.13 after three biological replicates
(Fig. 2A and Supplementary Table 2). Therefore, we tested
all three siRNAs targeting Spry2 that were identified as
hits in the primary screen. After nine biological replicates,
all three independent siRNAs to Spry2 statistically signif-
icantly reduced preIns1 mRNA levels in MIN6 cells after
FDR correction (Fig. 2B). All three siRNAs reduced Spry2
mRNA levels (Supplementary Fig. 3).
Spry2 Is a UPR Target
In many cell types, Spry2 negatively regulates Ras-MAPK
signaling (18). Since MAPK signaling is thought to posi-
tively regulate insulin transcription, we sought another
mechanism for Spry2’s positive influence on insulin pro-
duction (19). We hypothesized that Spry2 might play a
role in the UPR, as dominant negative Spry2 expression in
the mouse lens has been reported to increase ER stress
(20). Furthermore, SPRY2 was induced in human islets
treated with palmitate, which induces ER stress (21).
We first asked whether Spry2 is induced by estab-
lished chemical UPR inducers. Exposure of MIN6 cells
to the sarcoplasmic/endoplasmic reticulum calcium ATPase
(Serca) inhibitor thapsigargan increased Spry2 mRNA
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and protein expression (Fig. 3A and B). The degree of
upregulation was similar to that of Wfs1 mRNA, a gene
known to be upregulated by ER stress (22,23). The
N-linked glycosylation inhibitor and ER stress inducer
tunicamycin also increased Spry2 mRNA and protein
(Supplementary Fig. 4A and B). Mouse embryonic fibro-
blasts (MEFs) also upregulated Spry2 mRNA in response
to thapsigargan (Fig. 3C) or tunicamycin (Fig. 3D). How-
ever, MEFs deficient in PERK did not upregulate Spry2
mRNA in response to thapsigargan or tunicamycin. Fi-
nally, since knockdown of Wfs1 is known to increase ER
stress in b-cells, we asked whether knockdown of Wfs1
might also increase Spry2 expression in MIN6 cells
(24,25). Multiple siRNAs targeting Wfs1 increased Spry2
mRNA and Spry2 protein expression in the absence of any
other ER stress inducer (Fig. 3E and F). Notably, these
Wfs1 siRNAs were effective in knockdown of Wfs1 mRNA
(Supplementary Fig. 4C) and Wfs1 protein (Supplemen-
tary Fig. 4D) and in reducing preIns1 mRNA (Supplemen-
tary Fig. 4E).
Knockdown of Spry2 Triggers the UPR
Next, we hypothesized that Spry2 could play a role in
regulating the UPR. Knockdown of Spry2 by multiple in-
dependent siRNAs resulted in increased levels of the UPR
markers CHOP and spliced Xbp1 (Fig. 4A and B). BiP
expression did not increase after either Spry2 or Wfs1
knockdown (data not shown). To further confirm activa-
tion of the UPR, we examined the activation of the ER
stress sensor PERK and its target Eif2a after siRNA
knockdown of Spry2 or Wfs1. Both phospho-PERK and
phospho-Eif2a levels increased after either Spry2 or
Wfs1 knockdown (Fig. 4C–E). ATF4 and ATF6 levels did
not change after Spry2 knockdown (Supplementary Fig.
5). Since ER stress in b-cells can trigger apoptosis, we
measured the frequency of annexin V+ cells after Spry2
knockdown. Indeed, knockdown of Spry2 increased the
fraction of annexin V+ cells (Fig. 4F).
Spry2 Affects Serca2 Expression and ER Calcium
Levels
Since PERK activation can be triggered by low levels of ER
calcium, we measured ER calcium levels using the D1ER
cameleon reporter by flow cytometry (26,27). Treatment
of D1ER-expressing MIN6 cells with EDTA and ionomycin
resulted in an ;60% increase in the number of cells with
low levels of FRET, confirming our ability to monitor ER
calcium concentrations with D1ER (Supplementary Fig.
6A and B). When D1ER MIN6 cells were transfected
with anti-Wfs1 siRNAs, there was a 40% increase in ER
calcium–low cells, in line with what has been previ-
ously reported (26). Spry2 knockdown by two independent
siRNAs also increased the fraction of cells with low levels of
ER calcium by 25% (Fig. 5A).
Decreased ER calcium could be caused by increased
activity of IP3 receptors. However, neither IP1 levels
(a breakdown product of IP3) nor expression of PLCg1, a
producer of IP3 that can be regulated by Spry2, changed
after Spry2 knockdown (Supplementary Fig. 6C and D).
Phosphorylated PLCg1 was not detectable with or with-
out Spry2 knockdown (data not shown). Therefore, we
examined levels of Serca2 after Spry2 knockdown. Serca2
protein levels were reduced by 50% after Spry2 knockdown
(Fig. 5B and C), while mRNA levels were not changed (Fig.
5D), suggesting posttranscriptional control of Serca2 pro-
tein by Spry2.
Figure 2—Hit confirmation. A: preIns1mRNA by qRT-PCR with SEM from MIN6 cells transfected with the indicated siRNAs. Red indicates
genes known to be involved in human diabetes. P values were adjusted for multiple testing using the Benjamini-Hochberg method. For
P values, see Supplementary Table 2 (n = 3 for each siRNA). Genes are organized according to known functions. B: The indicated
siRNAs targeting Spry2 were transfected into MIN6 cells, and preIns1 mRNA was measured by qRT-PCR (n = 9). *P < 0.05, ***P <
0.001. GPCR, G-protein–coupled receptor; neg, negative; phos, phosphatase.
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Alleviating ER Stress Rescues Spry2’s Effect on Insulin
Production and b-Cell Survival
Since ER stress is known to impact insulin promoter
activity, we asked whether amelioration of ER stress could
restore insulin production in Spry2 knockdown cells.
Treatment with tauroursodeoxycholic acid (TUDCA) was
able to rescue the reduced insulin mRNA seen after Spry2
knockdown (Fig. 5E). Furthermore, TUDCA treatment
was able to partially rescue increased b-cell death in
MIN6 cells after Spry2 knockdown (Fig. 5F).
b-Cell–Specific Deletion of Spry2 Results in
Hyperglycemia and Hypoinsulinemia
To demonstrate a role for Spry2 in vivo, we crossed a
conditional allele of Spry2 to MIP1-CreERT mice (28,29)
(Fig. 6A). Since we were unable to identify a Spry2 anti-
body suitable for immunohistochemistry, we used droplet
digital PCR to measure ko efficiency from islet genomic
DNA. Compared with Spry2 wt/wt MIP1-CreERT mice
injected with tamoxifen (Spry2 wt), there was a 50% re-
duction in Spry2 islet genomic DNA in Spry2 flox/flox
MIP1-CreERT mice injected with tamoxifen (Spry2 b-ko)
(Supplementary Fig. 7A). The heterozygous Spry2 mice
(Spry2 b-het) showed an intermediate degree of reduc-
tion. As ;70% of the cells from islets are expected to
be b-cells, we estimate that the recombination efficiency
was approximately 70%. As Spry2 mRNA is present at
approximately twofold higher levels in the mouse a-cell
than in the mouse b-cell, we observed a modest but sig-
nificant reduction in Spry2 from total islet mRNA of these
animals (Supplementary Fig. 7B) (30). Protein levels of
Spry2 were reduced in Spry2 b-ko islets compared with
Spry2 b-het islets (Supplementary Fig. 7C and D).
We asked whether loss of Spry2 could result in changes
in glycemia. After glucose challenge, the Spry2 b-ko mice
were statistically significantly hyperglycemic relative to
either Spry2 wt or Spry2 b-het mice (Fig. 6B and C).
Spry2 b-ko mice also had lower plasma insulin levels
15 min after glucose injection (Fig. 6D), while their in-
sulin tolerances and weights were not different (Supple-
mentary Fig. 7E and F). Islets from Spry2 b-ko mice had
slightly lower levels of mature Ins1/2 mRNA, confirming
our findings in MIN6 cells (Fig. 6E).
Despite lower insulin mRNA levels, total pancreatic
insulin content normalized to total protein was not reduced
Figure 3—Spry2 is a UPR target. A: MIN6 cells were treated with the indicated concentrations of thapsigargan for 12 h and analyzed for
Spry2 orWfs1 expression by qRT-PCR (n = 6). B: As in A, but analyzed for Spry2 protein normalized to GAPDH expression (n = 4). C: MEFs
of the indicated genotype were stimulated with 500 nmol/L thapsigargan (Tg) or vehicle (DMSO) for 6 h and analyzed for Spry2 expression
by qRT-PCR (n = 6). D: As in C, but with 2.5 ug/mL of tunicamycin (Tn). E: MIN6 cells were transfected with the indicated siRNA targeting
Wfs1, and qRT-PCR was performed for Spry2 mRNA (n = 9). F: As in E, but Spry2 protein was quantitated by Western blot and normalized
to GAPDH protein (n = 3). For a representative blot, see Fig. 4C. SEM is plotted. *P < 0.05, **P < 0.01, ***P < 0.001. AU, arbitrary units.
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in the Spry2 b-ko as compared with b-het islets (Supple-
mentary Fig. 7G), and we also did not find any difference in
b-cell area in the Spry2 b-ko as compared with the Spry2
b-het mice (Supplementary Fig. 7H). Batch in vitro glucose-
stimulated insulin secretion of islets from Spry2 b-het or Spry2
b-ko mice was also not different (Supplementary Fig. 7I).
b-Cell–Specific Deletion of Spry2 Results in UPR
Activation in Islets
Confirming our data in MIN6 cells, phospho-PERK levels
were elevated in the islets of Spry2 b-ko mice as compared
with those from Spry2 wt mice (Fig. 6F and G). Phospho-
Eif2a levels and CHOP mRNA were also increased in Spry2
b-ko islets, but these increases did not reach our statistical
significance cutoff (P = 0.07 and P = 0.055, respectively)
(Fig. 6H and Supplementary Fig. 8A). As in MIN6 cells, we
did not detect differences in ATF4 in islets from Spry2
b-ko mice (Supplementary Fig. 8B), which suggests that
it is predominantly the PERK pathway that is activated
by Spry2 loss in the b-cell. Unlike in MIN6 cells, we did
not detect a difference in spliced Xbp1mRNA in Spry2 b-ko
islets (Supplementary Fig. 8A). We also did not detect a
difference in fasting proinsulin levels between Spry2 b-ko
and Spry2 b-het mice (Supplementary Fig. 8C).
DISCUSSION
We describe the first whole-genome RNAi screen for
regulators of the insulin promoter. In terms of absolute
insulin mRNA reduction, the strongest hits came from
knockdown of the well-known transcription factors Glis3,
NeuroD1, and Pdx1—perhaps not surprising since these
proteins bind directly to the insulin promoter. Other hits
were previously known to positively regulate insulin se-
cretion in the b-cell but not insulin transcription. For
example, Gpr142 was known to positively regulate insulin
secretion in vivo and in vitro, and we now identify it as a
potential regulator of insulin transcription (31,32). Gpr75
positively regulates insulin secretion in cell lines, and our
data further these findings by showing that loss of Gpr75
results in impaired insulin secretion in vivo (33). More
importantly, these data show that our screen was able to
identify regulators of b-cell function that are relevant
in vivo. Since most of our hits have no known connection
to b-cell function, the study of these novel regulators will
greatly expand our understanding of insulin regulation.
On a global level, this unbiased screen highlights
several critical pathways required for insulin transcrip-
tion. Multiple components of the oxidative phosphoryla-
tion cascade were identified as positive regulators of
Figure 4—Knockdown of Spry2 triggers the UPR. A: MIN6 cells were transfected with the indicated siRNAs, and qRT-PCR was performed
for CHOP (n = 9). B: As in A, but for spliced Xbp1 (n = 9). C: MIN6 cells were transfected with the indicated siRNAs, and Western blots were
run for the indicated proteins. This is a representative blot of 3–6 experiments. D: Quantitation of phospho-PERK normalized to total PERK
(n = 3–6). E: Quantitation of phospho-Eif2a normalized to total Eif2a (n = 3–6). F: MIN6 cells transfected with the indicated siRNAs and
annexin V+ cells were measured by flow cytometry (n = 9). SEM is plotted. *P < 0.05, **P < 0.01, ***P < 0.001.
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insulin mRNA production (Atp5a1, Atp5j2, Cox6b1, Cox6c,
Cox7a2). While oxidative phosphorylation is known to be
important in glucose sensing for insulin secretion, our
data suggests that it is also important for insulin tran-
scription (34).
ER stress and the UPR were another thematic area
identified by the screen. The UPR is known to reduce
insulin transcription through multiple mechanisms, in-
cluding ATF6 and spliced XBP1 (35–37). Besides Wfs1,
activation of the UPR likely also explains the hits involved
in vesicular trafficking between the ER and the Golgi
(Copb1, Gbf1, Sec23b). In fact, mice lacking the small
GTPase Sec23b lack professional secretory cells (including
b-cells) and have UPR activation in the embryonic pan-
creas (38).
We chose to focus on Spry2 because a SNP near the
gene is associated with type 2 diabetes. We show a novel
role for Spry2 in insulin transcription and glucose homeo-
stasis in vivo. Furthermore, we demonstrate that Spry2 is
both a target and a negative regulator of the PERK arm of
the UPR, suggesting that upregulation of Spry2 may be a
part of the homeostatic response to increased ER stress.
However, we were unable to detect a change in b-cell area
or in in vitro insulin secretion in Spry2 b-ko mice. Since
the hyperglycemia of the Spry2 b-ko mice was rela-
tively mild, we might only expect a small reduction in
these assays that could be below our limit of detection.
Therefore, the defect in the Spry2 b-ko islets could be
from reduced mass, reduced insulin secretion, or possibly
both.
Our data nonetheless demonstrate an explanation of
how a SNP near Spry2 might cause human diabetes—
through activation of the b-cell UPR. How could loss of
Spry2 activate the UPR? Although Spry1 and Spry2 have
been previously shown to bind to and negatively regulate
PLCg1 activity in non–b-cells, thereby reducing inositol
triphosphate production and calcium efflux from the ER,
we did not observe changes in PLCg1 phosphorylation or
increased inositol phosphate production (39). Instead, we
found that Spry2 knockdown in b-cells causes reduced
Serca2 protein levels, suggesting a possible mechanism by
which Spry2 loss might cause reduced ER calcium and the
UPR. However, since ER calcium concentrations can also be
reduced by high levels of ER stress, it remains possible that
Spry2 loss causes ER stress by an alternative mechanism,
such as accumulation of ubiquitylated proteins, decreased
autophagy, or altered vesicular traffic (20,26,40,41). Future
studies will be required to define how Spry2 loss results in
activation of the UPR.
In summary, we have performed the first whole-genome
RNAi screen in b-cells. We have identified novel and un-
expected positive regulators of the insulin promoter and
have begun to elucidate how these genes function together
to control pancreatic b-cell insulin production. Specifically,
Figure 5—Spry2 knockdown affects ER calcium. A: D1ER-expressing MIN6 cells were transfected with the indicated siRNAs. A total of
10,000 live events were analyzed for FRET, and the percent change in the frequency of cells with low ER calcium relative to the luciferase
control is plotted (n = 7–8). B: MIN6 cells were transfected with the indicated siRNAs, and the indicated proteins were measured by Western
blot (n = 9). C: Quantitation of B. D: MIN6 cells were transfected with the indicated siRNAs, and Serca2bmRNA was measured by qRT-PCR
(n = 3). E: MIN6 cells were transfected with the indicated siRNAs and treated with TUDCA (500 mmol/L) or vehicle for 24 h prior to harvest.
qRT-PCR for preIns1 was performed (n = 3). F: As in E, but percent dead cells was quantified by flow cytometry (n = 6). SEM is plotted. *P<
0.05, **P < 0.01, ***P < 0.001.
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we have demonstrated a novel role for Spry2 in the UPR
and in insulin production in b-cells, possibly explaining the
association between SNPs near Spry2 and type 2 diabetes
susceptibility. Further understanding of the role of Spry2
and the UPR may provide novel therapeutic inroads to
understand and treat human diabetes.
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